Brief: Biohaven Initiates Trial Of Drug For Treatment Of Migraine
30/09/2024 12:47
Sept 30 (Reuters) - Biohaven Ltd BHVN.N :
* BIOHAVEN INITIATES PIVOTAL TRIAL OF NOVEL INVESTIGATIONAL
DRUG
FOR TREATMENT OF MIGRAINE
* BIOHAVEN LTD - TRIAL TO ENROLL 575 PATIENTS ACROSS 60 U.S.
SITES
Source text for Eikon: urn:newsml:reuters.com:*:nPn7Q58Xja
Further company coverage: BHVN.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biohaven
See all newsActing US FDA chief meets with rare disease groups to mend fences (updated)
Acting US FDA chief meets with rare disease groups to mend fences
Brief: Biohaven Reports New Clinical Data In Epilepsy With Opakalim, A Selective Kv7.2/7.3 Activator, Highlighting Seizure Control And Markedly Differentiated Tolerability Profile
Brief: Biohaven Files For Offering Of Up To $350 Million Common Shares - SEC Filing
Brief: Biohaven Ltd Files For Mixed Shelf Offering Size Not Disclosed - SEC Filing